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Abstract We investigated the influence of assay choice on
the results in a two-tier testing algorithm for the detection of
anti-Borrelia antibodies. Eighty-nine serum samples from
clinically well-defined patients were tested in eight different
enzyme-linked immunosorbent assay (ELISA) systems
based on whole-cell antigens, whole-cell antigens supple-
mented with VlsE and assays using exclusively recombinant
proteins. A subset of samples was tested in five immuno-
blots: one whole-cell blot, one whole-cell blot supplemented
with VlsE and three recombinant blots. The number of IgM-
and/or IgG-positive ELISA results in the group of patients
suspected of Borrelia infection ranged from 34 to 59%. The
percentage of positives in cross-reactivity controls ranged
from 0 to 38%. Comparison of immunoblots yielded large
differences in inter-test agreement and showed, at best, a
moderate agreement between tests. Remarkably, some
immunoblots gave positive results in samples that had been
tested negative by all eight ELISAs. The percentage of
positive blots following a positive ELISA result depended
heavily on the choice of ELISA–immunoblot combination.
We conclude that the assays used to detect anti-Borrelia
antibodies have widely divergent sensitivity and specificity.
The choice of ELISA–immunoblot combination severely
influences the number of positive results, making the
exchange of test results between laboratories with different
methodologies hazardous.
Introduction
Lyme disease is caused by Borrelia spp. In Europe,
infection is mostly caused by B. afzelii and B. garinii,
while in the United States, B. burgdorferi sensu stricto is
the causative agent [1]. Lyme disease manifests in a myriad
of clinical ways, including erythema migrans, arthritis,
carditis and neuroborreliosis [1]. Extracutaneous Lyme
disease requires laboratory confirmation by culture, poly-
merase chain reaction (PCR) or antibody determination [2,
3]. Culture is only available in a limited number of
laboratories, and the value of PCR in the diagnosis of
various forms of Lyme disease is of limited use [2, 3].
Therefore, serological assays are the main method used to
diagnose extracutaneous forms of Lyme disease.
Current guidelines for the diagnosis of Lyme disease
include a two-tier testing algorithm [2, 3]. First, an enzyme-
linked immunosorbent assay (ELISA) is performed, fol-
lowed by the confirmation of positive ELISA results with
an immunoblot. This two-step procedure was initiated
because first-generation ELISAs for the detection of anti-
Borrelia antibodies lacked specificity. The inclusion of a
second, more specific, serological method made it possible
to exclude false-positive ELISA samples [2, 4].
Many diagnostic assays are currently commercially
available, and manufacturers have developed them to
increase their sensitivity and specificity. During the last
decade, assays using a peptide from the sixth invariant
region (C6) of the variable major protein-like sequence-
expressed (VlsE) of B. burgdorferi have been shown to be
promising [5, 6]. Laboratories can choose between ELISAs
and immunoblots using sonicated whole-cell antigens,
whole-cell antigens combined with recombinant antigens
(VlsE C6 peptide) and exclusively recombinant antigens.
Due to this array of serological tests, there are an almost
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and immunoblot in a two-tier testing scheme. Comparing
anti-Borrelia test results between laboratories and studies
may be impossible if tests with widely diverging sensitiv-
ities and specificities are used [7].
The aim of the present study was to compare a wide
range of ELISA assays and immunoblots, based on either
whole-cell or recombinant antigens, for detecting anti-
Borrelia antibodies. We also aimed to investigate the
influence of assay choice on results in a two-tier testing
algorithm (ELISA followed by immunoblot). Therefore, we
tested serum samples in eight ELISA systems and five
immunoblots, covering the entire spectrum of native and
recombinant antigens.
Patients and methods
Patients
Serum samples were selected from 89 clinically well-
defined individuals. Fifty-nine samples were from patients
suspected of Borrelia infection (skin manifestations, n=8;
neurological symptoms, n=26; arthritic symptoms, n=11;
ocular symptoms, n=4; other, n=10). Fourteen samples
were from healthy controls and 16 came from patients with
a high possibility for cross-reacting antibodies (syphilis
patients, n=10; Mycoplasma pneumonia-infected patients
based on symptoms consistent with M. pneumoniae
infection and a positive result for anti-M. pneumoniae
IgM and IgG with a Virion/Serion ELISA , n=6).
Methods
Serum samples were tested in eight different ELISA systems.
Three assays were based on sonicated whole-cell antigens
(Diacheck/Moran anti-Borrelia, VIDAS and Virion/Serion
ELISA Classic Borrelia burgdorferi), three assays with
sonicate whole-cell antigens supplemented with VlsE for
IgG anti-Borrelia antibodies (Dade Behring Enzygnost Lyme
link VlsE, Euroimmun Anti-Borrelia plus VlsE ELISA and
Genzyme Virotech Borrelia afzelii+VlsE ELISA) and two
assays using recombinant proteins (Immunetics C6 Lyme
ELISA Kit and Mikrogen recomWell Borrelia). A subset of
samples from 31 patients suspected of Borrelia infection
were also tested in five different immunoblots. This group
consisted of the following patients: skin manifestations, n=3;
neurological symptoms, n=15; arthritic symptoms, n=6;
ocular symptoms, n =2; other, n=5. One whole-cell blot
(home-made using B. afzelii strain A39 cell sonicate,
RIVM), one whole-cell blot supplemented with VlsE
(Viramed Borrelia “MiQ”+VlsE ViraBlot) and three recom-
binant blots (Euroimmun Euroline-RN-AT, Mikrogen recom
Line Borrelia and Genzyme Virotech Borrelia Europe Line).
A total of 31 samples were tested in all immunoblots.
Manufacturer-suggested cut-off levels and interpretation
criteria were used for the ELISAs and immunoblots.
Statistical analysis was performed using SPSS version
16.0 (SPSS Inc., Chicago, IL, USA).
Results
As expected, there was considerable discordance between
the eight ELISAs. We tested 89 samples from patients and
controls on all eight ELISAs. Of the complete set of serum
samples, 35/89 (39%) were negative in all assays, while 16/
89 (18%) were positive in all assays. The remaining 38/89
(43%) samples were positive in one to seven ELISAs.
In the 59 patients that were suspected of Borrelia
infection, we observed a wide range of positive results,
with percentages of positive ELISAs varying between 34
and 61% (Table 1). We did not observe a relation between
the fraction of positive results and the nature of antigen
used for the ELISA. The specificity of the ELISAs also
varied widely. Although we had only small numbers of
positive tests in healthy controls, some ELISAs produced
up to 38% of positive tests in the cross-reactivity group
(syphilis and M. pneumonia-infected patients).
We aggregated results from the IgM and IgG tests and
assessed them using a kappa statistic to determine agree-
ment between the ELISAs. The kappa values ranged from
0.41 (moderate agreement) to 0.79 (substantial to good
agreement), emphasising the differences between the
ELISAs (Table 2). The choice of antigen does not seem to
influence the level of agreement. Even the lowest kappa
values were observed between two ‘whole-cell+VlsE’
ELISAs (0.43).
We tested a subset of 31 serum samples from patients
suspected of Borrelia infection in all five immunoblots.
Samples were from patients with positive and negative
ELISA results, allowing us to investigate the specificity of
the immunoblots. In general, we observed a much lower
agreement for the immunoblots than for the ELISAs. Kappa
values ranged from 0 (poor agreement) to 0.84 (good
agreement), indicating that, for many samples, the outcome
of the immunoblot is highly dependent on the choice of
manufacturer (Table 3). Inter-blot agreement was disap-
pointingly low for IgM and much higher for IgG (Table 3).
Interestingly, recombinant blots did not have a higher
agreement than whole-cell blots, and there was limited
agreement even between recombinant blots. The highest
agreement was for the home-made whole-cell blot with the
Mikrogen recombinant blot. Additional analysis on the
individual band level revealed similarly poor agreement,
even in immunoblots containing recombinant antigens.
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different blots, there are 40 possible ELISA–blot combina-
tions. Thirty-one samples were tested in all 40 combina-
tions. A score of 0 indicates a negative result in all ELISAs
and all blots, while a score of 40 indicates a positive result
in all ELISAs and all blots. A score between 0 and 40
indicates that not all possible combinations yielded a
positive result (i.e. disagreement between various ELISA–
blot combinations). Of this small sample cohort, 20/31
(65%) had either a score of 0 or 40, indicating perfect
agreement, irrespective of the ELISA–blot combination
used. Discordant interpretations were generated in the other
35% of samples.
The influence of assay choice is further illustrated by
investigation of the relationship between each ELISA and
the fraction of positive blots. Surprisingly, we found anti-
Borrelia immunoblot reactivity in samples that were
negative in all eight ELISAs. These are samples that
normally would not have been tested in immunoblots.
Again, this was not dependent on the nature of the antigen
used for the immunoblot. For the Euroimmun immunoblot,
4/11 (36%) of the ELISA-negative samples were blot-
positive. Some immunoblots also seem to lack sensitivity,
since samples that were positive in six to all eight of the
tested ELISAs remained negative in all immunoblots. Some
of these samples were from Lyme disease patients with a
short duration of symptoms, confirming that ELISAs may
have a higher sensitivity than immunoblots during the early
phase of a Borrelia infection.
For some ELISA–blot combinations, only about half of
the ELISA-positive samples could be confirmed by
immunoblot (e.g. VIDAS ELISA–Virotech immunoblot,
Table 4). The quality of the other ELISAs was so high that
the majority of ELISA-positive samples were confirmed
with immunoblots (e.g. Diacheck/Moran and Enzygnost
ELISAs). When taking into account the lack of specificity
of a number of the immunoblots, it is clear that the
combination of a non-specific ELISA with a non-specific
blot will lead to a high fraction of presumably false-positive
test results.
The ELISA test value is the final factor influencing the
fraction of positive confirmatory blots. Figure 1 depicts an
example—values for the VIDAS and Immunetics C6 Lyme
ELISA according to the immunoblot results of a whole-cell
blot (home-made) and a recombinant blot (Mikrogen). For
the VIDAS–home-made blot combination, it is difficult to
indicate a cut-off value for the VIDAS ELISA with a good
separation between blot-positives and blot-negatives. When
using the Immunetics ELISA as a screening tool, it
becomes clear that, irrespective of the blot method used,
Table 1 Performance of eight enzyme-linked immunosorbent assay (ELISAs) in the three patient groups
ELISA
manufacturer
Antigen used
for ELISA
Number of positive samples (%) Total number of
tested samples
Patients suspected for Borrelia infection Cross-reactivity controls Healthy controls
Diacheck/Moran Whole-cell 20/59 (34%) 2/16 (13%) 1/14 (7%) 89
VIDAS Whole-cell 31/59 (53%) 4/16 (25%) 1/14 (7%) 89
Virion/Serion Whole-cell 24/59 (41%) 1/16 (6%) 0/14 89
Enzygnost Whole-cell+VlsE 23/59 (39%) 0/16 0/14 89
Euroimmun Whole-cell+VlsE 29/59 (49%) 3/16 (19%) 0/14 89
Virotech Whole-cell+VlsE 35/59 (59%) 6/16 (38%) 0/14 89
Immunetics Recombinant 22/59 (37%) 0/16 0/14 89
Mikrogen Recombinant 24/59 (41%) 3/16 (19%) 0/14 89
Table 2 Agreement between ELISAs for detecting IgM and/or IgG anti-Borrelia antibodies (kappa values)
ELISA manufacturer Antigen used for ELISA Diacheck/Moran VIDAS Virion/Serion Enzygnost Euroimmun Virotech Immunetics
Diacheck/Moran Whole-cell - - - - - - -
VIDAS Whole-cell 0.53 - - - - - -
Virion/Serion Whole-cell 0.67 0.69 - - - - -
Enzygnost Whole-cell+VlsE 0.71 0.62 0.78 - - - -
Euroimmun Whole-cell+VlsE 0.71 0.45 0.56 0.56 - - -
Virotech Whole-cell+VlsE 0.44 0.65 0.57 0.43 0.47 - -
Immunetics Recombinant 0.74 0.60 0.64 0.86 0.53 0.41 -
Mikrogen Recombinant 0.79 0.53 0.63 0.68 0.67 0.44 0.65
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These characteristics make it possible to define groups of
ELISA-positive serum samples that do not need immuno-
blot confirmation.
Discussion
We studied the influence of the choice of detection method
on the results of Borrelia serology. We found that Borrelia
ELISAs and immunoblots for detecting anti-Borrelia anti-
bodies have widely divergent sensitivity and specificity,
and that immunoblots generally show limited agreement.
Analysis of a large number of ELISA–immunoblot combi-
nations revealed large differences between various test
strategies in a two-tier testing algorithm. Although we only
studied a limited number of serum samples, our extensive
approach allowed us to draw several conclusion based on
our observations.
Theoretically, the use of recombinant antigens should
lead to increased specificity and, possibly, increased
sensitivity as well. This does not seem to be true for the
currently available ELISAs and immunoblots for the
detection of anti-Borrelia antibodies. We could not find a
clear relationship between the fraction of positive tests, the
specificity and the nature of the antigen used for the
serological tests. ELISAs using sonicated whole-cell anti-
gens can be sensitive and specific, while recombinant
ELISAs may lack specificity. Therefore, manufacturer
claims for the superior performance of assays using
Table 4 Fractions of blot-confirmed samples for 40 ELISA–immunoblot combinations
ELISA manufacturer Antigen used
for ELISA
Number of positive
samples in ELISA/total
number of samples
Blot
Whole-cell Whole-cell+VlsE Recombinant
Home-made Virablot Euroimmun Mikrogen Virotech
Diacheck/Moran Whole-cell 12/31 11/12 (92%) 9/12 (75%) 11/12 (92%) 12/12 (100%) 9/12 (75%)
VIDAS Whole-cell 19/31 11/19 (58%) 12/19 (63%) 13/19 (68%) 14/19 (74%) 10/19 (53%)
Virion/Serion Whole-cell 15/31 11/15 (73%) 11/15 (73%) 13/15 (87%) 12/15 (80%) 9/15 (60%)
Enzygnost Whole-cell+VlsE 12/31 11/12 (92%) 10/12 (83%) 10/12 (83%) 12/12 (100%) 10/12 (83%)
Euroimmun Whole-cell+VlsE 14/31 11/14 (79%) 11/14 (79%) 12/14 (86%) 12/14 (86%) 9/14 (64%)
Virotech Whole-cell+VlsE 17/31 11/17 (65%) 11/17 (65%) 13/17 (77%) 13/17 (77%) 9/17 (53%)
Immunetics Recombinant 13/31 11/13 (85%) 10/13 (77%) 10/13 (77%) 13/13 (100%) 10/13 (77%)
Mikrogen Recombinant 13/31 11/13 (85%) 9/13 (69%) 11/13 (85%) 12/13 (92%) 9/13 (69%)
Blot Blot type Home-made Virablot Euroimmun Mikrogen Virotech
IgM and IgG combined
Home-made Whole-cell - - - - -
Virablot Whole-cell+VlsE 0.55 - - - -
Euroimmun Recombinant 0.45 0.24 - - -
Mikrogen Recombinant 0.74 0.42 0.29 - -
Virotech Recombinant 0.66 0.60 0.25 0.55 -
IgM
Home-made Whole-cell - - - - -
Virablot Whole-cell+VlsE −1.57 - - - -
Euroimmun Recombinant 0.04 0.20 - - -
Mikrogen Recombinant 0.42 0 0.26 - -
Virotech Recombinant 0.20 0.46 0.39 0.34 -
IgG
Home-made Whole-cell - - - - -
Virablot Whole-cell+VlsE 0.43 - - - -
Euroimmun Recombinant 0.43 0.24 - - -
Mikrogen Recombinant 0.84 0.27 0.43 - -
Virotech Recombinant 0.71 0.63 0.30 0.56 -
Table 3 Agreement between
immunoblots for detecting
anti-Borrelia antibodies (kappa
values)
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bodies must be interpreted with caution.
A two-tier testing algorithm for the detection of anti-
Borrelia antibodies is recommended world-wide [2, 3, 6].
However, there are several reasons to reappraise the
additional value of an immunoblot confirmatory test in a
two-tier testing scheme.
First, the lack of specificity of some immunoblots is
counter-intuitive. The immunoblot is used as a confirmatory
test, although it can be argued that it is merely a supplemental
test due to the inter-dependence of ELISAs and immunoblots
[8]. Theoretically, the use of recombinant antigens should
allow discrimination between a specific antibody reactivity,
cross-reactive antibodies and true anti-Borrelia antibodies
[4]. The presence of commercially available immunoblots
with low specificity diminishes the value of the immunoblot
as a confirmatory test [8]. Furthermore, the two-tier testing
scheme was originally proposed to overcome the lack of
specificity of Borrelia ELISAs. This study has shown that
not all of the newer generation ELISAs using recombinant
Borrelia antigens have improved specificity compared to
older serological assays [9, 10].
Second, the low level of agreement between the different
immunoblots is very disappointing, especially for IgM.
This low level of agreement, even at the individual band
level, makes it hard to compare immunoblot results from
different manufacturers.
Third, a mismatch between immunoblot and ELISA may
occur during the early phase of infection. There are numerous
examples—from this and other studies—in which patients
with early Lyme disease were initially ELISA-positive and
blot-negative [11]. In such cases, immunoblot seroconver-
sion can only be documented in a follow-up sample, and,
sometimes, even this option is blocked because antibiotic
treatment may interfere with the development of the anti-
Borrelia antibody response [12]. This is an example of better
sensitivity in the ELISAs compared to the immunoblots.
Without detailed knowledge of the clinical manifestations
and illness duration, reporting these cases as ‘negative’ could
lead to erroneous conclusions.
Finally, several groups can be discriminated based on the
ELISA value [10]: a ‘high positive’ group exhibiting
clinical symptoms consistent with a diagnosis of Lyme
disease and which can be reported as ‘positive’ without
confirmatory testing, a ‘low positive’ group in which
confirmatory testing may be helpful and, lastly, a negative
group that does not require any further investigation. We do
not advocate abandoning the use of immunoblots to
confirm anti-Borrelia antibodies, but we do think that only
a selection of samples needs confirmatory blotting. Fur-
thermore, knowledge about the lower sensitivity of immu-
noblots compared to some of the ELISAs is indispensable
in interpreting results.
In conclusion, ELISAs and immunoblots for detecting
anti-Borrelia antibodies have widely divergent sensitivity
and specificity, and immunoblots for detecting anti-Borrelia
antibodies have only limited agreement. Therefore, the
choice of ELISA–immunoblot combination severely influ-
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Fig. 1 Enzyme-linked immuno-
sorbent assay (ELISA) test val-
ues in relation to immunoblot
results for the detection of anti-
Borrelia antibodies
Eur J Clin Microbiol Infect Dis (2011) 30:1027–1032 1031ences the number of positive results, making the exchange
of test results between laboratories with different method-
ologies hazardous. The widespread availability of more
specific and sensitive assays for the detection of anti-
Borrelia antibodies will open the way for a reappraisal of
the two-tier testing system.
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